Understanding Three Key Tumour Markers: AFP, Beta-HCG & LDH
Learn what tumour markers AFP, Beta-HCG, and LDH measure, what elevated levels may indicate, and how these biomarkers are used in health screening across the UK.
What Are Tumour Markers AFP, Beta-HCG, and LDH?
Tumour markers are proteins or substances that can be measured through a simple blood test, providing insight into specific biological processes occurring within the body. AFP (Alpha-Fetoprotein), Beta-HCG (Beta-Human Chorionic Gonadotropin), and LDH (Lactate Dehydrogenase) are three such markers commonly included in UK health screening panels — particularly within more comprehensive or advanced packages.
These biomarkers are not exclusive to any single condition. They may be associated with a range of physiological states, from entirely normal variations to changes that may warrant further clinical investigation. It is important to understand the difference between cancer screening and cancer diagnosis, as tumour markers contribute data points to support a broader picture of your health rather than providing definitive conclusions.
Practical Insight: Tumour markers are not used in isolation to confirm or rule out any condition. They are most meaningful when interpreted alongside clinical history, symptoms, and trends over time — ideally with the guidance of a qualified healthcare professional.
AFP, Beta-HCG, and LDH at a Glance
The table below provides a quick overview of each marker, what it measures, and the approximate normal reference range for adults.
| Marker | Full Name | Produced By | Commonly Associated With | Normal Range (Approximate) |
|---|---|---|---|---|
| AFP | Alpha-Fetoprotein | Liver, yolk sac | Liver health, germ cell activity | < 10 ng/mL in adults |
| Beta-HCG | Beta-Human Chorionic Gonadotropin | Trophoblastic cells | Pregnancy, germ cell activity | < 5 mIU/mL in non-pregnant adults |
| LDH | Lactate Dehydrogenase | Most body tissues | Tissue turnover, cellular stress | 140–280 U/L (varies by lab) |
Practical Insight: Reference ranges may vary slightly between laboratories depending on the analytical methods used. Always refer to the specific ranges provided on your results report for accurate interpretation.
Understanding AFP (Alpha-Fetoprotein)
AFP is a glycoprotein primarily produced by the foetal liver and yolk sac during development. In non-pregnant adults, AFP levels are normally very low. When levels are found to be elevated, it may prompt further investigation, although elevated AFP does not confirm any specific condition on its own.
Elevated AFP may be associated with:
- Liver conditions, including chronic inflammation or cirrhosis
- Certain germ cell-related changes
- Benign liver conditions such as hepatitis
- Pregnancy (a normal and expected cause of elevation)
Including AFP in a screening panel can provide a useful baseline — particularly for individuals with lifestyle or family risk factors related to liver health. Learn more about the health screening tests that help detect cancer early.
Practical Insight: If you have a family history of liver concerns or regularly consume alcohol, establishing a baseline AFP level through screening can be a sensible step — providing a reference point for future comparison.
Understanding Beta-HCG (Beta-Human Chorionic Gonadotropin)
Beta-HCG is widely recognised as a pregnancy hormone, produced by trophoblastic cells following implantation. In healthy, non-pregnant individuals, Beta-HCG levels are typically negligible. An unexpected elevation in a non-pregnant individual may warrant further clinical exploration.
In non-pregnant adults, elevated Beta-HCG may be associated with:
- Germ cell activity or related changes
- Certain non-cancerous conditions
- Physiological variations, particularly in older adults
When Beta-HCG is included in a blood testing panel, it adds an additional layer of information — particularly useful for individuals seeking a thorough and proactive approach to their health monitoring. For men, this marker is especially relevant in the context of testicular cancer blood screening.
Practical Insight: Even small changes in Beta-HCG levels over time can be meaningful. Having a baseline measurement allows clinicians to identify trends rather than relying on a single snapshot, which supports more informed clinical decision-making.
Understanding LDH (Lactate Dehydrogenase)
LDH is an enzyme found in nearly all living cells throughout the body. It plays a role in energy production and is released into the bloodstream when cells are damaged or under stress. Because LDH is present in so many tissues, an elevated level is non-specific — it can reflect a wide range of conditions and states.
Elevated LDH may be linked to:
- Strenuous exercise or physical exertion
- Muscle injury or tissue trauma
- Liver or kidney changes
- Haemolytic processes (red blood cell breakdown)
- Inflammatory conditions
LDH is often included in comprehensive screening panels because it serves as a general indicator of tissue health and cellular integrity. When elevated, it signals the need for context — further tests or clinical review may help determine the underlying cause.
Practical Insight: An elevated LDH level on its own is not necessarily a cause for concern. Vigorous exercise within 24–48 hours before a blood test can cause a temporary rise. Context — including your activity levels and other results — is essential for accurate interpretation.
Who Should Consider Tumour Marker Testing?
Tumour marker testing with AFP, Beta-HCG, and LDH may be particularly relevant for individuals who:
- Wish to establish a baseline measurement for future comparison as part of proactive health monitoring
- Have a family history of liver conditions, germ cell changes, or related concerns
- Are interested in a comprehensive screening approach that goes beyond standard NHS panels
- Have lifestyle factors that may affect liver health, such as regular alcohol consumption or occupational exposures
- Simply want to take a proactive approach to understanding their body and tracking biomarker trends over time
Exploring screening packages that include these markers can be a straightforward way to gain additional insight into your current health status. This is particularly relevant given that germ cell tumours are among the most common cancers in young men aged 15 to 49 in the UK.
How Often Should You Have Tumour Markers Tested?
The appropriate frequency of tumour marker testing depends on individual circumstances. As a general guide:
- Annual screening: For most adults seeking proactive monitoring, an annual test can help track trends and detect meaningful changes over time
- Every 6 months: Individuals with known risk factors — such as a strong family history or previous abnormal results — may benefit from more frequent testing
- One-off baseline: Even a single test can be valuable if you have never had these markers checked before, providing a reference point for any future testing
Your healthcare provider can advise on the most appropriate frequency based on your personal health profile and any specific concerns.
What Do Your Results Mean?
Interpreting tumour marker results requires context. Results are typically categorised as follows:
- Within normal range: Levels fall within expected parameters for your age and sex. No immediate action is typically required, though results can serve as a valuable baseline for future comparison.
- Mildly elevated: Slightly above the reference range. This may be caused by benign conditions, recent illness, vigorous exercise, or physiological variation. Follow-up testing is often recommended to assess whether the elevation persists.
- Significantly elevated: Levels that are notably above the expected range may warrant further clinical investigation, which could include additional blood tests, imaging, or referral to a specialist.
Practical Insight: Trends over time are generally more meaningful than any single reading. Establishing a baseline allows you and your healthcare provider to identify patterns and make informed decisions about whether further investigation may be warranted.
Tumour Marker Testing in London: Private Screening vs NHS Pathways
Within the NHS, tumour marker tests such as AFP, Beta-HCG, and LDH are typically requested when there is a specific clinical indication — for example, as part of an investigation following symptoms or as a monitoring tool for an existing condition. They are not routinely included in standard NHS health checks or screening programmes.
Private health screening offers an alternative pathway for individuals who wish to include these markers as part of a proactive, preventive approach. Through a private clinic, you can access tumour marker testing without the need for a GP referral, often with faster turnaround times and detailed results reports.
If you are based in London and would like to explore your options, Health Screening Clinic offers a range of screening packages that include AFP, Beta-HCG, and LDH alongside other key biomarkers — providing a thorough and accessible approach to health monitoring.
Frequently Asked Questions
What are tumour markers AFP, Beta-HCG, and LDH used for?
These biomarkers are used as part of health screening to provide insight into specific biological processes. AFP relates primarily to liver health and germ cell activity, Beta-HCG is associated with pregnancy and germ cell changes, and LDH reflects general tissue turnover and cellular stress. Together, they contribute to a more comprehensive picture of your health.
Can tumour marker blood tests detect cancer?
Tumour markers can sometimes highlight changes that may be associated with cancer, but they cannot confirm or rule out a diagnosis on their own. Many non-cancerous conditions can also cause elevated levels. These tests are most valuable when interpreted as part of a broader clinical picture, alongside symptoms, history, and other investigations.
Are AFP, Beta-HCG, and LDH tests available in London without a GP referral?
Yes. Private health screening clinics in London offer direct access to tumour marker testing without the need for a GP referral. You can book a blood test that includes AFP, Beta-HCG, and LDH as part of a comprehensive screening package or as individual tests.
How is the blood test for tumour markers carried out?
The test involves a straightforward blood draw from a vein, usually in the arm. The process takes just a few minutes and is carried out by a qualified healthcare professional. The blood sample is then sent to an accredited laboratory for analysis.
What does an elevated AFP level mean?
An elevated AFP level may be associated with liver conditions such as cirrhosis or hepatitis, certain germ cell-related changes, or pregnancy. It does not confirm any specific diagnosis. Further investigation — potentially including additional blood tests, imaging, or specialist referral — may be recommended to determine the underlying cause.
Can Beta-HCG be elevated in men?
Yes. While Beta-HCG is best known as a pregnancy marker, it can be elevated in men in certain circumstances. This may include germ cell-related activity or, rarely, other physiological or clinical conditions. Any unexpected elevation in a male should be discussed with a healthcare professional for further assessment.
Is LDH a specific tumour marker?
LDH is considered a non-specific marker. It is present in nearly all body tissues and can be elevated due to a wide range of causes, including exercise, muscle injury, infection, liver or kidney changes, and inflammatory conditions. Its value lies in contributing context when assessed alongside other markers and clinical information.
How long does it take to receive tumour marker results?
With private health screening, results for AFP, Beta-HCG, and LDH are typically available within 2–5 working days, depending on the laboratory. Your screening provider will advise on the expected turnaround time when you book your appointment.
Should I fast before a tumour marker blood test?
Fasting is not typically required for AFP, Beta-HCG, or LDH testing. However, if your screening package includes additional markers such as glucose or lipid panels, you may be advised to fast for 8–12 hours beforehand. Your clinic will provide specific preparation instructions when you book.
How often should I repeat tumour marker testing?
For most adults, annual screening is a sensible approach to track trends over time. Individuals with specific risk factors or previous abnormal results may benefit from testing every 6 months. A one-off baseline test is also valuable if you have never had these markers checked before. Your healthcare provider can advise on the most appropriate frequency for your circumstances.
Taking a Proactive Approach to Your Health
Understanding what tumour markers AFP, Beta-HCG, and LDH measure — and what your results may indicate — is a positive step towards informed, proactive health management. Whether you are establishing a baseline for the first time, monitoring trends over time, or exploring a more comprehensive approach to screening, these biomarkers can offer valuable insights as part of a well-rounded health assessment.
If you would like to explore screening options that include AFP, Beta-HCG, and LDH, visit Health Screening Clinic to learn more about our available packages.
About This Article
This content has been developed in line with UK medical editorial standards, drawing upon established clinical guidance and evidence-based health information. All content is reviewed to ensure compliance with GMC advertising guidance, CQC patient communication standards, and ASA regulatory requirements. Our aim is to provide clear, trustworthy, and educational health information that empowers informed decision-making.
Health Screening Clinic provides testing and reporting only. We do not provide medical diagnoses, prescriptions, or treatment. If you have concerns about your results or symptoms, please seek medical advice from appropriate healthcare services. In case of severe symptoms, seek urgent medical care.
Last reviewed: March 2026 | Next review due: March 2027